Menu
Search
|

Menu

Close
X

Beigene Ltd BGNE.OQ (NASDAQ Stock Exchange Global Select Market)

124.40 USD
-- (--)
As of Jul 18
Previous Close 124.40
Open --
Volume --
3m Avg Volume 96,925
Today’s High --
Today’s Low --
52 Week High 194.56
52 Week Low 105.19
Shares Outstanding (mil) 60.00
Market Capitalization (mil) 7,338.13
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY19
78
FY18
198
FY17
238
FY16
1
EPS (USD)
FY19
-0.216
FY18
-0.921
FY17
-0.183
FY16
-0.274
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.10
Price to Sales (TTM)
vs sector
30.13
7.99
Price to Book (MRQ)
vs sector
4.62
4.39
Price to Cash Flow (TTM)
vs sector
--
24.00
Total Debt to Equity (MRQ)
vs sector
15.02
17.94
LT Debt to Equity (MRQ)
vs sector
14.46
12.82
Return on Investment (TTM)
vs sector
-42.36
12.64
Return on Equity (TTM)
vs sector
-49.80
17.18

EXECUTIVE LEADERSHIP

John Oyler
Executive Chairman of the Board, Chief Executive Officer, Since 2010
Salary: $97,664.00
Bonus: $1,272,070.00
Xiaobin Wu
General Manager, China and President, Since 2018
Salary: --
Bonus: --
Howard Liang
Chief Financial Officer and Chief Strategy Officer, Since 2015
Salary: --
Bonus: --
Eric Hedrick
Interim Chief Medical Officer, Immuno-Oncology, Since 2019
Salary: --
Bonus: --
Jane Huang
Chief Medical Officer, Hematology, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Mourant Governance Services
94 Solaris Avenue, Camana Bay
GRAND CAYMAN     KY1-1108

Phone: +1345.9494123
Site:

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

SPONSORED STORIES